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ment of hyperuricemia and gout.
Objective: The goal of this study was to examine the impact of coadministration of probenecid on the
pharmacokinetic parameters and tolerability of olmesartan in healthy volunteers.
Methods: In a randomized, open-label, 2-way crossover study, 12 volunteers received 2 oral treatments
(olmesartan alone or olmesartan plus probenecid) separated by 4 days. Blood samples were obtained for
a 48-hour pharmacokinetic evaluation after drug administration. Tolerability was assessed by monitoring
vital signs and laboratory tests before and after administration of the study drug.
Results: Pharmacokinetic parameters were evaluated in 6 male and 6 female healthy volunteers (mean
age, 22 [range, 20–25] years]; weight, 56.0 [range, 51.0–60.0] kg). Probenecid coadministration increased
olmesartan Css-av, AUC0-1, and AUC0–48 by 40%, 50%, and 50%, respectively (P ¼ 0.018, 0.000, 0.000,
respectively), but there was no statistical signiﬁcance for Tmax, t1/2, Css-max, and Css-min between
olmesartan plus probenecid and olmesartan alone (P ¼ 0.697, 0.053, 0.521, and 0.734, respectively).
No serious adverse event (AE) was reported during the study. The proportion of volunteers with AEs in
the olmesartan plus probenecid period (5 of 12 [42%]) was higher than that in the olmesartan-alone
period (1 of 12 [8%]). All of the AEs during the olmesartan plus probenecid period were abnormal routine
urine test results. The AE in olmesartan-alone period was dizziness. All AEs were classiﬁed as mild and
considered to be at least possibly related to treatment. All volunteers recovered from the AEs by 2 weeks
after the end of the study.
Conclusions: Probenecid increases the exposure speed of olmesartan by increasing the AUC0–48, AUC0-1,
and Css-av. The combined treatment of olmesartan medoxomil with probenecid may increase the
occurrence of genitourinary side effects. ClinicalTrials.gov identiﬁer: NCT01907373.
& 2014. The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Hypertension and hyperuricemia are widespread conditions.
There is signiﬁcant overlap of the 2 conditions. Serum uric acid
(SUA) is currently recognized as a risk factor for cardiovascular
disease.1 Thus, at some point in their therapy, hypertensive
patients with hyperuricemia are likely to require concurrent
treatment with antihypertensive and hypouricemic agents. ForPublished by Elsevier Inc. All right
r the terms of the Creative
Works License, which per-
ion in any medium, provided
njia Lake Road 582#, Yuelu
).this reason, it is important to determine whether there are any
pharmacokinetic interactions resulting from the concomitant
administration of such agents.
Probenecid is a well-established hypouricemic agent for the
treatment of hyperuricemia and gout and is thought to act on
urate transporter 1 (URAT1),2,3 a novel member of the organic
anion transporter (OAT) family, thereby increasing uric acid
excretion in the kidney by blocking urate reuptake and resulting
in a decrease in SUA.4
Olmesartan is an angiotensin II receptor antagonist and is
effective and well tolerated in the treatment of arterial hyper-
tension.5 Olmesartan is orally administered in olmesartan medox-
omil, the prodrug form.6,7 The recommended dose of olmesartan
ranges from 20 to 80 mg once daily. There is no relationship
between the dose and the occurrence of side effects of olmesartans reserved.
Table I
Drug administration schedule.
Period I
Treatment Day 1 Day 2 Day 3 Day 4
Olmesartan medoxomil, mg 20 20 20 20
Blood sample ▲ ▲ ▲ ▲*
Washout time (4 days)
Period II
Treatment Day 1 Day 2 Day 3 Day 4
Olmesartan medoxomil, mg 20 20 20 20
Probenecid, mg — — — 500 500
Blood sample ▲ ▲ ▲ ▲*
▲, Venous blood samples (5 mL) were collected pre-dose.
nVenous blood samples (5 mL/time) were obtained at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,
12, 24, 36, and 48 hours after olmesartan medoxomil administration.
K.-Y. Li et al. / Current Therapeutic Research 76 (2014) 7–108medoxomil. The mean oral bioavailability of olmesartan medox-
omil in healthy adult volunteers has been found to be 29%. Cmax
occurs at 2 hours (range, 1–4 hours). Distribution of olmesartan
occurs over the ﬁrst 8 hours after oral administration with an
estimated volume of distribution of 29 L. Olmesartan is primarily
excreted unchanged in the feces (up to 89%), with a small
proportion (10%–16%) excreted unchanged in the urine. Because
the rate of renal clearance (mean, 0.55 L/h) is substantially lower
than the glomerular ﬁltration rate, it was hypothesized that there
is extensive tubular reabsorption of olmesartan. The mean elim-
ination half-life was 5 to 7 hours in Chinese patients and 12 to 18
hours in Western patients, with a duration of action of up to 24
hours.7 In vitro studies show that OAT polypeptides 1B1 and 1B3
are involved in hepatobiliary and renal transport of olmesartan.6,8
We know that probenecid interferes with the kidneys’ OAT.2,3 Will
probenecid have an effect on the pharmacokinetics of olmesartan,
thereby resulting in changes in the antihypertensive effect and
side effects of olmesartan? Until now, many clinical studies have
shown that olmesartan has no pharmacokinetic interactions with
other drugs; moreover, there is no research on the interactions
between olmesartan and probenecid. In this study, we assess the
involvement of probenecid in the pharmacokinetics and tolerabil-
ity of olmesartan.Subjects and Methods
Study design
This study had an open-label, randomized-sequence, multiple-
dose, 2-treatment, 2-period design. The protocol was approved by
the Ethics and Research Committee of the Hunan Provincial Tumor
Hospital, and the study was performed in accordance with the
current revision of the Declaration of Helsinki9 concerning medical
research in humans and with current Good Clinical Practice (the
European Union) guidelines10 and the Technical Guideline for
Chemical Drug Clinical Pharmacokinetic Study (China Food and
Drug Administration).11 The study was conducted in August 2009.
The national study registration number for the study was
2005L01077. The dose of 20 mg/d for olmesartan medoxomil and
500 mg/time for probenecid were chosen for this study according
to the recommended doses in clinic.12,13 Subjects underwent
2 consecutive 4-day treatment periods (period I: olmesartan
medoxomil, 20 mg once daily for 4 days; period II, olmesartan
medoxomil 20 mg once daily for 4 days plus probenecid 500 mg
twice daily on the last day). The ﬁrst dose of probenecid was
administered with olmesartan medoxomil in the morning of the
last day in period II. The second dose of probenecid was admin-
istered alone 6 hours after the ﬁrst administration. The treatment
periods were separated by a washout period of 4 days. Subjects
arrived at the hospital the day before the study. A table of random
numbers was used to assign the sequence for subjects to receive
multiple doses (administered with 200 mL of water) of olmesartan
medoxomil tablets (Lot: 070901; expiration: September 2009,
TianQuan Pharmaceutical Co., Ltd, Fujian, China), with or without
a probenecid tablet together (Lot: 081201; expiration: December
2010, Shanghai Sine Pharmaceutical Co., Ltd.). Subjects could not
consume anything other than water for 12 hours before and
2 hours after administration of the study drug. The drug admin-
istration schedule is shown in Table I.
Subjects
Healthy female and male Chinese subjects were recruited
through the Phase I Trial Unit at the Hunan Provincial Tumor
Hospital (Afﬁliated Tumor Hospital of Xiangya Medical School ofCentral South University) via advertisement. Written informed
consent was obtained from all of the subjects after an explanation
of the aim and the risks of the study before study initiation. The
main information in the informed consent included the details of
the tested drugs, the purpose and the length of the study, the
number of visits required, and the medical procedures and
medications included. It also provided expected outcomes, poten-
tial beneﬁts, and possible risks. Subjects were compensated for
study participation. Subjects were eligible based on the following
criteria: age 18 to 40 years and a body mass index between 19 and
25 kg/m2. Additional inclusion criteria were nonsmoking status
and an unremarkable clinical history. No volunteers could have a
history or evidence of a renal, gastrointestinal, hepatic, or hema-
tologic abnormality; any acute or chronic disease; or an allergy to
any drugs. These subjects were excluded to ensure that the
degrees of variation were not due to the inﬂuence of illness or
other medications. Chest radiography, electrocardiography, bio-
chemistry, hematology, and routine urine test results were used to
conﬁrm subject history. Subjects were required to have negative
HIV and hepatitis В and C test results.
Blood sampling and assaying
A 20-gauge catheter was placed in a forearm vein. The schedule
for drawing the blood samples is shown in Table I. The blood
samples were drawn into vacuum tubes with heparin sodium as an
anticoagulant and centrifuged at 1500g (r ¼ 0.03 m) for 10 min-
utes. The separated plasma was stored at 401C until analyzed by
ultraperformance LC-MS/MS. The concentrations of olmesartan in
plasma samples were determined as described previously.14
Brieﬂy, Strata-X SPE (solid-phase extraction) cartridges (Phenom-
enex, Torrance, California) were used to extract olmesartan from
plasma. Olmesartan was analyzed in the ultraperformance LC-MS/
MS system (10.0-cm column length, 2.1-mm inner diameter,
3.0-mm particle size; Welchrom XB-CN, Welch Materials, Ellicott
City, Maryland). The LC system (ACQUITY UPLC, Waters, Man-
chester, United Kingdom) was coupled with a Waters Quattro
Premier XE triple quadrupole with an ion-source electrospray
probe (Waters Corporation, Milford, Massachusetts). The method
was validated over the concentration range of 2 to 1600 ng/mL for
olmesartan. The limit of quantiﬁcation was 2 ng/mL. The intraday
precision and interday precision were o7% and 8%, respectively.
The intraday accuracy and interday accuracy were 90.5% to 101.8%
and 91.3% to 100.4% respectively.
Tolerability
Tolerability was assessed by monitoring vital signs (blood
pressure, heart rate, and respiratory rate at baseline [0] and at 1,
2, 3, 6, 12, 36, and 48 hours) after administration of the study drug
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section, were performed at baseline and 24 hours after admin-
istration of the study drug in each period. Subjects were inter-
viewed during the study by the physician concerning the
occurrence of adverse events (AEs). The tolerability information
of all subjects was recorded in detail on the case-report forms.2.00
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Figure. Log-transformed concentration-time curves after administration of olme-
sartan alone and olmesartan plus probenecid.Data and statistical analyses
The pharmacokinetic parameters of olmesartan were obtained
by noncompartmental analysis with the Drug and Statistics Pro-
gram Package (DAS, Version 2.0.1, Wannan Medical College, Wuhu,
China). The elimination rate constant (λz) was obtained as the slope
of the linear regression of the log-transformed concentration values
versus time data in the terminal phase. The t1/2 was calculated as
0.693/λz. Tmax, Cmax, and Cmin were read directly from the observed
concentration versus time proﬁles. AUC0–t was calculated by the
linear trapezoidal rule. AUC0-1 was calculated as AUC0-1 ¼
AUC0–t þ Ct/λz, where Ct was the last measurable concentration.
The log-transformed parameters, including AUC0-1, AUC0-48, Cmin,
t1/2, and Cmax, were subjected to analysis of paired-sample t tests.
ANOVA was used to analyze log-transformed Cmin for the intra-
period on 3 different days (days 2, 3, and 4). A nonparametric test
(Wilcoxon signed rank test) was performed for Tmax. Statistical
signiﬁcance was set at P o 0.05.Results
Demographic characteristics
Twenty volunteers were assessed for eligibility. Of them, 6 male
and 6 female healthy Chinese subjects (mean age, 22 [range, 20–
25] years of age; weight, 56.0 [range, 51.0–60.0] kg) were enrolled
in the study. All volunteers completed the study.Pharmacokinetic properties
The plasma pharmacokinetic parameters of olmesartan-alone
(period I) and olmesartan plus probenecid (period II) are summar-
ized in Table II.
Log-transformed concentration-time curves are shown in the
Figure.
Olmesartan mean plasma concentrations in period II were 40%
higher than that in period I (P ¼ 0.018). There was statistical
signiﬁcance for AUC0-1 and AUC0–48 between the 2 periods (P ¼
0.000 and 0.000, respectively). The AUC0-1 and AUC0–48 in period
II increased nearly 50% of that in period I, but there was no
statistical signiﬁcance for Tmax, t1/2, Css-max, and Css-min between
the 2 periods (P ¼ 0.697, 0.053, 0.521, and 0.734, respectively).
There was also no statistical signiﬁcance for Cmin on 3 different
days (days 2, 3, and 4) between the intraperiod (period II [P ¼
0.998] and period I [P ¼ 0.919]).Table II
Pharmacokinetic parameters of olmesartan.
Period AUC0–48 (ng/mL/h) AUC0-1 (ng/mL/h) t1/2 (h)
I
Mean 4849.703 4927.619 6.392
SD 1845.364 1887.675 1.239
II
Mean 7007.432 7192.630 7.697
SD 2865.966 3064.606 1.757
P 0.000 0.000 0.053Tolerability assessments
No serious AE was reported during the study, and no volunteer
withdrew from the study. The proportion of volunteers with AEs in
period II (5 of 12 [42%]) was higher than that in period I (1 of 12
[8%]). All of the AEs in period II were abnormal routine urine test
results 24 hours after olmesartan plus probenecid administration.
The abnormal results were as follows: for volunteer 3, protein
(3þ), red blood cells (3þ), white blood cells (1þ), glucose (1þ);
for volunteer 5, protein (3þ), glucose (1þ); for volunteer 10,
white blood cells (1þ), glucose (2þ); for volunteer 11, red blood
cells (1þ), white blood cells (1þ); for volunteer 12: glucose (2þ).
The AE in olmesartan-alone period was dizziness. All AEs were
classiﬁed as mild and considered to be at least possibly related to
treatment. All volunteers recovered from the AEs by 2 weeks after
the end of the study.Discussion
In the current study, Cmin, Css-max, Tmax, and t1/2 did not changed
signiﬁcantly when olmesartan is combined with probenecid. As
we know, olmesartan medoxomil is converted to olmesartan by
intestinal wall esterases. Olmesartan undergoes virtually no fur-
ther metabolism.13 Thus, the pharmacokinetics of olmesartan were
considered less likely to be affected by the drugs metabolized or to
have effects on the CYP450 isoenzyme system,15–17 for example,
probenecid. At the same time, the tubular excretion with which
probenecid interferes plays a small role in the excretion of
olmesartan.
The changes in AUC0–48, AUC0-1, and Css-av in the study have
statistical signiﬁcance when olmesartan is combined with probe-
necid in healthy subjects. Css-av for the olmesartan plus probenecid
period was 40% higher than that for the olmesartan-alone period.Tmax (h) Css-max (ng/mL) Css-min (ng/mL) Css-av (ng/mL)
1.458 894.409 37.604 185.562
0.396 300.610 25.282 68.155
1.625 805.253 29.773 261.309
0.433 219.337 16.415 90.349
0.697 0.521 0.734 0.018
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period increased by nearly 50% of that of the olmesartan-alone
period. The increase in olmesartan exposure may or may not
increase the antihypertensive efﬁcacy; this is not yet clear. More
basic and clinical studies are needed to answer these questions.
There is another interesting result in that olmesartan exposure
(AUC) is increased 40%, but the increase in exposure has no effect
on either absorption (Tmax, Cmax) or elimination (t1/2). In the study,
we only studied the concentration of olmesartan in blood. In fact,
the drug does not only distribute blood but in tissue as well.
Sometimes the AUC may change without absorption or elimination
may change if the distribution balance between blood and tissue
is changed. Unfortunately, we did not obtain body tissue to study
the drug concentrations. So our study is underpowered in some
sense.
In this study, 42% of the volunteers in the olmesartan plus
probenecid period had abnormal routine urine test. The urine tests
are performed at baseline, 24 hours after olmesartan administration
alone in period I, and 24 hours after olmesartan plus probenecid
administration in period II. The AEs are considered to be at least
possibly related to treatment. The genitourinary side effects including
urinary tract infection with olmesartan were reported in only 0.5% to
1% of patients. Hematuria was reported in 41% of patients, but at
the same or greater incidence than with placebo.18 The genitourinary
side effects of probenecid including bloody urine, difﬁcult or painful
urination, cloudy urine, sudden decrease in the amount of urine, and
frequent urge to urinate are o1%.19 The occurrence of AEs may not
be increased by the increase in olmesartan exposure because there is
no relationship between the dose and the occurrence of side effects
with olmesartan medoxomil.13 We suspect the combined treatment
of olmesartan medoxomil with probenecid may be not safe. Is there
any additive or increased effect on AEs when olmesartan medoxomil
and probenecid are administered together? More studies are needed
to determine this.Conclusions
In this small study of healthy Chinese volunteers, probenecid
increases the exposure speed of olmesartan by increasing the
AUC0–48, AUC0-1, and Css-av, but has no effects on other pharma-
cokinetic parameters of olmesartan. The combined treatment of
olmesartan medoxomil and probenecid may increase the occur-
rence of genitourinary side effects.Acknowledgments
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